Abstract
The purpose of this study was to characterize cytokine responses during conditioning in patients undergoing allogeneic stem cell transplantation (SCT) with the aim to identify which markers that may reliably reflect inflammatory activity during conditioning. We investigated inflammatory and anti-inflammatory mediators in plasma samples drawn daily during the conditioning of 20 patients. Soluble tumour necrosis factor α receptor I (sTNFRI) increased during the conditioning reflecting the type of conditioning given. Antithymocyte globulin (ATG) was the most potent inducer of sTNFRI (288% increase (median) P=0.002), followed by VP-16 (184%, P=0.03), cyclophosphamide (129%, P=0.03) and total body irradiation (148%, P=0.0005). Administration of i.v. busulfan (Busilvex; BU) was not associated with significant changes in sTNFRI levels. At day 0 (the day of stem cell infusion) the sTNFRI levels were not only elevated compared with baseline (188% increase), P<0.0001), they also correlated with the baseline values (r=0.72, P=0.0003). The levels of tumour necrosis factor, interleukin (IL)-1β, IL-6, IL-8, IL-10 and IL-12 stayed at low levels during the conditioning, except from a transient increase in the levels of IL-6, IL-8, IL-10 and IL- receptor antagonist (IL-Ra) seen after ATG infusion. These findings suggest that further investigation of circulating sTNFRI levels may be of interest in studies of prognostic factors in SCT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al. Bone marrow transplantation. N Engl J Med 1975; 292: 895–902.
Loberiza F . International Bone Marrow Transplant Registry Newsletter 2003.
Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB . Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994; 83: 2360–2367.
Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL . Total body irradiation and acute graft versus host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204–3213.
Ferrara JLM, Antin JH . The pathophysiology of graft-versus-host disease. In: Thomas ED, Blume K, Forman S (eds). Bone Marrow Transplantation. Blackwell Science: Berlin, 1999, pp 305–315.
Holler E, Kolb HJ, Hintermeier-Knabe R, Mittermuller J, Thierfelder S, Kaul M et al. Role of tumour necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. Transplant Proc 1993; 25: 1234–1236.
Hill GR, Teshima T, Gerbitz A, Pan L, Cooke KR, Brinson YS et al. Differential roles of IL-1 and TNFα on graft-versus-host disease and graft versus leukemia. J Clin Invest 1999; 104: 459–467.
Remberger M, Ringden O, Markling L . TNFα levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplant 1995; 15: 99–104.
Herve P, Flesch M, Tiberghien P, Wijdenes J, Racadot E, Bordigoni P et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992; 79: 3362–3368.
Holler E, Kolb HJ, Mittermüller J, Kaul M, Ledderose G, Duell T et al. Modulation of graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 1995; 86: 890–899.
Abdallah AN, Boiron JM, Attia Y, Cassaigne A, Reiffers J, Iron A . Plasma cytokines in graft versus host disease and complications following bone marrow transplantation. Hematol Cell Ther 1997; 39: 27–32.
Chasty RC, Lamb WR, Gallati H, Roberts TE, Brenchley PE, Yin JA . Serum cytokine levels in patients undergoing bone marrow transplantation. Bone Marrow Transplant 1993; 12: 331–336.
Sakata N, yasui M, Okamura T, Inoue M, Yumura-Yagi K, Kawa K . Kinetics of plasma cytokines after hematopoietic stem cell transplantation from unrelated donors: the ratio of plasma IL-10/sTNFR level as a potential prognostic marker in severe acute graft-versus-host disease. Bone Marrow Transplant 2001; 27: 1153–1161.
Takatsuka H, Takemoto Y, Yamada S, Wada H, Tamura S, Fujimori Y et al. Complications after bone marrow transplantation are manifestations of systemic inflammatory response syndrome. Bone Marrow Transplant 2000; 26: 419–426.
Sardas OS, Beksac M, Koc H, Ilhan O, Akan H, Gurman G . Tumor necrosis factor alpha in human bone marrow recipients. Blood 1990; 76: 2639–2640.
Feldmann M . Development of anti-TNF therapy for rheumatoid arthritis. Nature Rev Immunol 2002; 2: 364–371.
O’Shea JJ, Ma A, Lipsky P . Cytokines and autoimmunity. Nature Rev Immunol 2002; 2: 37–45.
Choy EH, Panayi GS . Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907–916.
Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D . Stabilization of the bioactivity of tumor necrosis factor by its receptors. J Exp Med 1992; 175: 323–329.
Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF . Tumour necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89: 4845–4849.
Giradin E, Roux-Lombard P, Grau GE, Suter P, Gallati H, Dayer JM . Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. Immunology 1992; 76: 20–23.
Stark GL, Dickinson AM, Jackson GH, Taylor PR, Proctor SJ, Middleton PG . Tumour necrosis factor receptor type II 196 M/R genotype correlates with circulating soluble receptor levels in normal subjects and with graft versus host disease after sibling allogeneic bone marrow transplantation. Transplantation 2003; 76: 1742–1749.
Andersen LS, Petersen J, Bendtzen K . Production of interleukin (IL)-1b, IL-1 receptor antagonist and IL-10 by blood mononuclear cells in chronic arthritis. Cytokine 2000; 12: 62–68.
Or R, Kalinkowich A, Nagler A, Weisman Z, Naparstek E, Weiss L et al. Soluble tumor necrosis factor receptors: a possible prognostic marker for bone marrow transplantation related complications. Cytokines Mol Ther 1996; 2: 243–250.
Kashuap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2002; 8: 493–500.
Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF et al. Cytokine gene polymorphism in human disease: on-line databases. Genes Immunity 1999; 1: 3–19.
Morita C, Horiuchi T, Tsukamoto H, Hatta N, Kikuchi Y, Arinobu Y et al. Association of tumor necrosis factor receptor type II polymorphism 196R with systemic lupus erythematosus in the japanese. Arthritis Rheum 2001; 44: 2819–2827.
Shamim Z, Ryder LP, Heilmann C, Madsen HO, Svejgaard A, Jacobsen N et al. Genetic polymorphisms in the genes encoding human interleukin-7α. Biol Blood Marrow Transplant 2005; 11: 1.
Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002; 3: 673–680.
Krenger W, Hill GR, Ferrara JL . Cytokine cascades in acute graft-versus-host disease. Transplantation 1997; 64: 553–558.
Acknowledgements
The study was supported by The Danish Research Council, the Danish Biotechnology Programme, The Lundbeck Foundation, The H:S Research Programme, The Dagmar Marshall Foundation, The Research Foundation for Copenhagen, Faeroe Islands and Greenland, The Frænkel Foundation, Lily Benthine Lund's Foundation. The skilled technical assistance of Marianna Thomsen and Lone Bredahl is highly appreciated.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Andersen, J., Heilmann, C., Jacobsen, N. et al. Differential effect of conditioning regimens on cytokine responses during allogeneic stem cell transplantation. Bone Marrow Transplant 37, 635–640 (2006). https://doi.org/10.1038/sj.bmt.1705295
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705295
Keywords
This article is cited by
-
High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma
Bone Marrow Transplantation (2021)
-
Prognostic impact of the dosage of methotrexate combined with tacrolimus for graft-versus-host disease prophylaxis after cord blood transplantation
International Journal of Hematology (2021)
-
Cytokine serum levels during post-transplant adverse events in 61 pediatric patients after hematopoietic stem cell transplantation
BMC Cancer (2015)
-
Dynamic change of glycemic status during the early phase after allogeneic hematopoietic stem cell transplantation
Bone Marrow Transplantation (2015)
-
Administration of anti-thymocyte globulin: a comparison of two protocols
Bone Marrow Transplantation (2014)